Next-Generation Biologics: Viral Vectors, mRNA & Emerging Modalities

Course Summary

The biologics industry is rapidly expanding beyond conventional recombinant proteins and monoclonal antibodies into advanced therapeutic platforms such as viral vectors, mRNA therapeutics and other emerging modalities.

These technologies offer significant therapeutic opportunities but introduce unique challenges related to development complexity, manufacturing scalability, analytical characterisation, regulatory pathways and commercialisation.

This one-day program provides a structured understanding of next-generation biologics platforms and their strategic implications. Participants explore viral-vector development, mRNA therapeutics, platform comparison, technology-selection frameworks and business considerations.

The program combines scientific understanding with strategic decision-making, helping cross-functional leaders evaluate technology opportunities, assess risks and develop appropriate development strategies.

Who Should Attend

• Biologics R&D Scientists
• Advanced Therapy Development Teams
• CMC Professionals
• Process Development Scientists
• MSAT Professionals
• Manufacturing and Operations Teams
• Regulatory Affairs Professionals
• Pharma Strategy and Business Development Teams
• Innovation and Portfolio Management Teams
• Leaders evaluating emerging therapeutic platforms

Business Outcomes

Participants will be able to:

• Understand the evolution of next-generation biologics platforms.
• Evaluate the development complexity of viral vectors and mRNA technologies.
• Identify manufacturing and scalability challenges across emerging modalities.
• Compare therapeutic platforms using technical and commercial parameters.
• Understand regulatory and CMC considerations influencing development strategy.
• Assess partnership, platform-selection and investment decisions.
• Improve cross-functional alignment between scientific and business teams.